Search Results - "Wang, Miaozhou"

Elevated expression of TUBA1C in breast cancer predicts poor prognosis by Zhao, Yi, Wang, Wenwen, Li, Jinming, Du, Jiarui, Xie, Qiqi, Wang, Miaozhou, Liu, Zhen, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda, Shen, GuoShuang

“…α1C-tubulin ( TUBA1C ) is a member of the α-tubulin family and has served as a potential biomarker in a variety of cancers in many studies. In this study, the…”
Get full text

Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis by Liu, Zhilin, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Li, Zitao, Chen, Yongzhi, Huang, Shifen, Liu, Zhen, Zhao, Yi, Wang, Miaozhou, Li, Huihui, Xu, ZhengBo, Shen, Guoshuang, Zhao, Jiuda

“…Triple-negative breast cancer (TNBC) is a life-threatening subtype of breast cancer with limited treatment options. Therefore, this network meta-analysis (NMA)…”
Get full text

Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis by Li, Jinming, Shen, Guoshuang, Wang, Miaozhou, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Yi, Zhao, Jiuda

“…Neoadjuvant treatment options for triple-negative breast cancer (TNBC) are abundant, but the efficacy of different combinations of treatment options remains…”
Get full text

Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy by Zhao, Fuxing, Li, Enxi, Shen, Guoshuang, Dong, Qiuxia, Ren, Dengfeng, Wang, Miaozhou, Zhao, Yi, Liu, Zhen, Ma, Jinhua, Xie, Qiqi, Liu, Zhilin, Li, Zitao, Gao, Lihong, Zhao, Jiuda

“…Background Almost all adjuvant chemotherapy regimens for gastric cancer recommended by guidelines are fluorouracil (5-FU) based, and 5-FU-based adjuvant…”
Get full text

Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis by Wang, Tianzhuo, Shen, Guoshuang, Li, Jinming, Huo, Xingfa, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…The optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast…”
Get more information

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis by Tang, Yuyao, Shen, Guoshuang, Xin, Yuanfang, Li, Zhoujuan, Zheng, Yonghui, Wang, Miaozhou, Liu, Zhen, Zhao, Yi, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Background: The use of antibody–drug conjugates for the treatment of advanced-stage human epidermal growth factor receptor 2 (HER2)-low expression in breast…”
Get full text

Watson for oncology decision system for treatment consistency study in breast cancer by Liu, Yaobang, Huo, Xingfa, Li, Qi, Li, Yishuang, Shen, Guoshuang, Wang, Miaozhou, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhen, Zhao, Jiuda, Liu, Xinlan

“…The Watson for Oncology (WFO) decision system has been rolled out in many cancers. However, the consistency of treatment for breast cancer is still unclear in…”
Get full text

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis by Huo, Xingfa, Shen, Guoshuang, Wang, Tianzhuo, Li, Jinming, Xie, Qiqi, Liu, Zhen, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Many systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases. However, it is…”
Get full text

Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis by Zheng, Yonghui, Shen, Guoshuang, Zhang, Chengrong, Huo, Xingfa, Xin, Yuanfang, Fang, Qianqian, Guan, Yumei, Zhao, Fuxing, Ren, Dengfeng, Liu, Zhen, Wang, Miaozhou, Zhao, Jiuda

“…Anti-human epidermal growth factor receptor-2 (anti-HER2) therapy has shown excellent efficacy in patients with HER2 overexpression and amplification. Although…”
Get full text

Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis by Shi, Mingqiang, Li, Zhoujuan, Shen, Guoshuang, Wang, Tianzhuo, Li, Jinming, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Metastatic triple-negative breast cancer (mTNBC) is an aggressive histological subtype with poor prognosis. Several first-line treatments are currently…”
Get full text

Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis by Zhao, Fuxing, Shen, Guoshuang, Dong, Qiuxia, Xin, Yuanfang, Huo, Xingfa, Wang, Miaozhou, Liu, Zhen, Zhao, Yi, Ren, Dengfeng, Xie, Qiqi, Liu, Zhilin, Li, Zitao, Gao, Lihong, Du, Feng, Zhao, Jiuda

“…Although platinum-based chemotherapy can improve pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC), the impact on…”
Get full text

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis by Zhao, Fuxing, Huo, Xingfa, Wang, Miaozhou, Liu, Zhen, Zhao, Yi, Ren, Dengfeng, Xie, Qiqi, Liu, Zhilin, Li, Zitao, Du, Feng, Shen, Guoshuang, Zhao, Jiuda

“…The predictive strength and accuracy of some biomarkers for the pathological complete response (pCR) to neoadjuvant therapy for HER2-positive breast cancer…”
Get full text

Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis by Li, Zhoujuan, Shen, Guoshuang, Shi, Mingqiang, Zheng, Yonghui, Guan, Yumei, Xin, Yuanfang, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…A high body mass index (BMI) can indicate overweight or obesity and is a crucial risk factor for breast cancer survivors. However, the association between high…”
Get full text

Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort by Ning, Lizhi, Liu, Yaobang, Hou, Yujin, Wang, Miaozhou, Shi, Mingqiang, Liu, Zhen, Zhao, Jiuda, Liu, Xinlan

“…On average, 5–10% of patients are diagnosed with metastatic breast cancer (MBC) at the initial diagnosis. This study aimed to develop a nomogram to predict the…”
Get full text

Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis by Li, Jinming, Shen, Guoshuang, Liu, Zhen, Liu, Yaobang, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Xie, Qiqi, Li, Zitao, Liu, Zhilin, Zhao, Yi, Ma, Fei, Liu, Xinlan, Xu, Zhengbo, Zhao, Jiuda

“…Background The wide use of antibody‐drug conjugates (ADCs) is transforming the cancer‐treatment landscape. Understanding the treatment‐related adverse events…”
Get full text

Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis by Yang, Ping, Zhang, Hengheng, Wu, Meijie, Zhao, Fuxing, Wang, Miaozhou, Zhao, Jiuda, Zhao, Yi

“…Background With the widespread use of CDK4/6 inhibitors, the number of discontinuations and reductions due to adverse events is increasing. Therefore, we…”
Get full text

Cytochrome b561 regulates iron metabolism by activating the Akt/mTOR pathway to promote Breast Cancer Cells proliferation by Zhou, Xiaofeng, Guo, Xinjian, Han, Jingqi, Wang, Miaozhou, Liu, Zhen, Ren, Dengfeng, Zhao, Jiuda, Li, Zhanquan

“…Breast cancer (BC) is the leading cause of cancer-related mortality in women, necessitating the development of novel therapeutic targets. While cytochrome b561…”
Get full text

Identification of the GTPase IMAP family as an immune-related prognostic biomarker in the breast cancer tumor microenvironment by Huo, Xingfa, Shen, Guoshuang, Li, Jinming, Wang, Miaozhou, Xie, Qiqi, Zhao, Fuxing, Ren, Dengfeng, Dong, Qiuxia, Zhao, Jiuda

“…•Breast cancer related differentially expressed genes were identified based on TCGA database and GTEx database.•The GIMAP family genes with relatively high…”
Get full text

Third-line Treatment for Metastatic Triple-negative Breast Cancer: A Systematic Review and Network Meta-analysis by Shi, Mingqiang, Li, Zhoujuan, Wang, Tianzhuo, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Metastatic triple-negative breast cancer (mTNBC) is an invasive histologic subtype with a poor prognosis and rapid progression. Currently, there is no standard…”
Get full text

Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis by Zhang, Hengheng, Shen, GuoShuang, Yang, Ping, Li, Jinming, Li, Zitao, Liu, Zhen, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Liu, Zhilin, Zhao, Jiuda, Zhao, Yi

“…Numerous studies have reported the efficacy of antibody–drug conjugates (ADCs) for treating breast cancer. However, during cytotoxic drug treatment, long-term…”
Get full text